Provided by Tiger Trade Technology Pte. Ltd.

SL Science Holding Ltd

1.57
-0.0300-1.88%
Post-market: 1.660.0900+5.73%18:59 EDT
Volume:52.27K
Turnover:85.65K
Market Cap:879.20M
PE:-2.44
High:1.75
Open:1.69
Low:1.57
Close:1.60
52wk High:14.50
52wk Low:1.42
Shares:560.00M
Float Shares:226.86M
Volume Ratio:0.39
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6447
EPS(LYR):-0.4532
ROE:-25.62%
ROA:-14.70%
PB:185.86
PE(LYR):-3.46

Loading ...

Massive Insider Move Signals Bold Confidence at SL Science Holding Ltd

TIPRANKS
·
Yesterday

SL Science Holding CEO Ching-Dong Wang Reports US$ 2.27 Million Common Share Purchase

Reuters
·
Yesterday

SL Science Seeks NASDAQ Home-Country Exemptions from Board Independence, Annual Meeting, Proxy, Shareholder Approval Rules

Reuters
·
Sep 25

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

GlobeNewswire
·
Sep 03

SL Science Holding VP of Finance Johnson Lau Resigns Effective Aug. 31

Reuters
·
Sep 02

SL Science Files FDA Drug Master File for GDT Cell-Derived Exosomes

MT Newswires Live
·
Aug 27

SL Science Holding Replaces ARK Pro CPA with TAAD as Auditor

Reuters
·
Aug 27

Sl Science Highlights New FDA Drug Master File for Gdt Cell-Derived Exosomes, Expanding the Regulatory Foundation of Its Platform

THOMSON REUTERS
·
Aug 27

SL Science Notifies Availability of Press Release on WCP 2026 Glioblastoma Research Update

Reuters
·
Jul 17

Sl Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

THOMSON REUTERS
·
Jul 17

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

GlobeNewswire
·
Jul 17

Sector Update: Healthcare

MT Newswires Live
·
Jul 11

SL Science Says FDA Acknowledges Orphan Drug Designation Request for Glioblastoma Cell Therapy

Reuters
·
Jul 10

Sl Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for Gdt Cell Therapy Targeting Glioblastoma

THOMSON REUTERS
·
Jul 10

Top Midday Decliners

MT Newswires Live
·
Jun 23

SL Science 2025 Net Loss Widens, Revenue Falls

MT Newswires Live
·
Jun 19

SL Science FY25 net loss widens to USD 3.82 million; revenue falls 35% to USD 2.2 million

Reuters
·
Jun 19

Sl Science Holding Limited Reports Full Year 2025 Financial Results

THOMSON REUTERS
·
Jun 19

Press Release: SL Science Holding Limited Reports Full Year 2025 Financial Results

Dow Jones
·
Jun 19

SL Science Holding files Form 3 as CEO Ching-Dong Wang reports 333,832,129 shares beneficially owned

Reuters
·
Jun 19